Zydus Cadila, a Rs. 9,400 crore plus pharma giant from Ahmedabad, has received the final approval from the US Food and Drug Administration (FDA) to market methotrexate tablets USP, 2.5 mg, a chemotherapy drug used for leukaemias, lymphomas, breast cancer, lung cancer, head and neck cancers and other cancers.
The drug will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.